[Relevance of COMT inhibitors in the treatment of motor fluctuations].
Stellenwert der COMT-Hemmer in der Therapie motorischer Fluktuationen.
Entacapone
Motor fluctuations
Opicapone
Parkinson’s disease
Tolcapone
Journal
Der Nervenarzt
ISSN: 1433-0407
Titre abrégé: Nervenarzt
Pays: Germany
ID NLM: 0400773
Informations de publication
Date de publication:
Oct 2022
Oct 2022
Historique:
accepted:
18
10
2021
pubmed:
20
1
2022
medline:
12
10
2022
entrez:
19
1
2022
Statut:
ppublish
Résumé
Catechol O‑methyltransferase (COMT) inhibitors have been established in the treatment of Parkinson's disease for more than 20 years. They are considered the medication of choice for treating motor fluctuations. The available COMT inhibitors, entacapone, opicapone and tolcapone, differ pharmacokinetically in terms of their half-lives with implications for the dose frequency, in their indication requirements and in their spectrum of side effects, including diarrhea and yellow discoloration of urine. Many patients with motor fluctuations are currently not treated with COMT inhibitors and are, therefore, unlikely to receive individually optimized drug treatment. This manuscript summarizes the results of a working group including several Parkinson's disease experts, in which the value of COMT inhibitors was critically discussed. Seit über 20 Jahren haben sich die COMT(Catechol-O-Methyltransferase)-Hemmer in der Therapie des Parkinson-Syndroms etabliert. Sie gelten als Mittel der Wahl bei motorischen Fluktuationen. Die verfügbaren Substanzen Entacapon, Opicapon und Tolcapon unterscheiden sich pharmakokinetisch hinsichtlich ihrer Halbwertszeiten, mit Folgen für die Einnahmefrequenz, hinsichtlich ihrer Indikationsvoraussetzungen und ihres Nebenwirkungsspektrums, darunter Diarrhöen und eine Gelbverfärbung des Urins. Viele Patienten mit motorischen Fluktuationen werden aktuell nicht mit COMT-Hemmern behandelt und erhalten deshalb vermutlich keine individuell optimale medikamentöse Therapie. Das vorliegende Manuskript fasst die Ergebnisse eines Arbeitstreffens mehrerer Parkinson-Experten zusammen, in dem der Stellenwert der COMT-Hemmer kritisch diskutiert wurde.
Autres résumés
Type: Publisher
(ger)
Seit über 20 Jahren haben sich die COMT(Catechol-O-Methyltransferase)-Hemmer in der Therapie des Parkinson-Syndroms etabliert. Sie gelten als Mittel der Wahl bei motorischen Fluktuationen. Die verfügbaren Substanzen Entacapon, Opicapon und Tolcapon unterscheiden sich pharmakokinetisch hinsichtlich ihrer Halbwertszeiten, mit Folgen für die Einnahmefrequenz, hinsichtlich ihrer Indikationsvoraussetzungen und ihres Nebenwirkungsspektrums, darunter Diarrhöen und eine Gelbverfärbung des Urins. Viele Patienten mit motorischen Fluktuationen werden aktuell nicht mit COMT-Hemmern behandelt und erhalten deshalb vermutlich keine individuell optimale medikamentöse Therapie. Das vorliegende Manuskript fasst die Ergebnisse eines Arbeitstreffens mehrerer Parkinson-Experten zusammen, in dem der Stellenwert der COMT-Hemmer kritisch diskutiert wurde.
Identifiants
pubmed: 35044481
doi: 10.1007/s00115-021-01237-3
pii: 10.1007/s00115-021-01237-3
doi:
Substances chimiques
Antiparkinson Agents
0
Catechol O-Methyltransferase Inhibitors
0
Levodopa
46627O600J
Tolcapone
CIF6334OLY
COMT protein, human
EC 2.1.1.6
Catechol O-Methyltransferase
EC 2.1.1.6
Types de publication
Journal Article
Review
Langues
ger
Sous-ensembles de citation
IM
Pagination
1035-1045Informations de copyright
© 2022. The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature.
Références
Antonini A, Ebersbach G, Rascol O et al (2020) Efficacy of opicapone in different treatment regimens in Parkinson’s disease patients with motor fluctuations. Park Relat Disord 79:e64–e65 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
doi: 10.1016/j.parkreldis.2020.06.239
Aquino CC, Fox SH (2015) Clinical spectrum of levodopa-induced complications. Mov Disord 30(1):80–89
pubmed: 25488260
doi: 10.1002/mds.26125
Armstrong MJ, Okun MS (2020) Diagnosis and treatment of Parkinson disease: a review. JAMA 323(6):548–560
pubmed: 32044947
doi: 10.1001/jama.2019.22360
Barichella M, Cereda E, Pezzoli G (2009) Major nutritional issues in the management of Parkinson’s disease. Mov Disord 24(13):1881–1892
pubmed: 19691125
doi: 10.1002/mds.22705
Borovac JA (2016) Side effects of a dopamine agonist therapy for Parkinson’s disease: a mini-review of clinical pharmacology. Yale J Biol Med 89(1):37–47
pubmed: 27505015
pmcid: 4797835
Buhmann C, Bihler M, Emich K et al (2019) Pill swallowing in Parkinson’s disease: a prospective study based on flexible endoscopic evaluation of swallowing. Park Relat Disord 62:51–56
doi: 10.1016/j.parkreldis.2019.02.002
Campbell NR, Hasinoff BB (1991) Iron supplements: a common cause of drug interactions. Br J Clin Pharmacol 31(3):251–255
pubmed: 2054263
pmcid: 1368348
doi: 10.1111/j.1365-2125.1991.tb05525.x
Carta M, Carlsson T, Muñoz A et al (2010) Role of serotonin neurons in the induction of levodopa- and graft-induced dyskinesias in Parkinson’s disease. Mov Disord 1:174–179
doi: 10.1002/mds.22792
Cattaneo C, La Ferla R, Bonizzoni E et al (2015) Long-term effects of safinamide on dyskinesia in mid- to late-stage parkinson’s disease: a post-hoc analysis. J Parkinsons Dis 5(3):475–481
pubmed: 26406127
pmcid: 4923744
doi: 10.3233/JPD-150569
Cenci MA, Lundblad A (2006) Post- versus presynaptic plasticity in L‑DOPA-induced dyskinesia. J Neurochem 99(2):381–392
pubmed: 16942598
doi: 10.1111/j.1471-4159.2006.04124.x
Chaudhuri KR, Poewe W, Brooks D (2018) Motor and nonmotor complications of levodopa: phenomenology, risk factors, and imaging features. Mov Disord 33:909–919
doi: 10.1002/mds.27386
Cilia R, Akpalu A, Sarfo FS et al (2014) The modern pre-levodopa era of Parkinson’s disease: insights into motor complications from sub-Saharan Africa. Brain 137(10):2731–2742
pubmed: 25034897
pmcid: 4163032
doi: 10.1093/brain/awu195
Corvol J, Artaud F, Cormier-Dequaire F et al (2018) Longitudinal analysis of impulse control disorders in Parkinson disease. Neurology 91:e189–e201
pubmed: 29925549
pmcid: 6059034
doi: 10.1212/WNL.0000000000005816
ClinicalTrials.gov (2021) eArly levoDopa with Opicapone in Parkinson’s paTients wIth motOr fluctuatioNs [ADOPTION] study. EudraCT-Nummer 2020-002754-24. https://clinicaltrials.gov/ct2/show/NCT04990284?term=2020-002754-24&draw=2&rank=1 . Zugegriffen: 11. Okt. 2021
Ebersbach G, Rascol O, Ferreira JJ et al (2020) Efficacy/safety of opicapone in Parkinson’s disease patients according to duration of motor fluctuations: post-hoc analysis of BIPARK‑I and II. Park Relat Disord 79:e63–e64 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
doi: 10.1016/j.parkreldis.2020.06.236
Orion Pharma (2019) Fachinformation Comtess
Roche Pharma (2020) Fachinformation Madopar
Bial – Portela & Ca (2020) Fachinformation Ongentys
MEDA Pharma (2020) Fachinformation Tasmar
Ferreira JJ, Lees A, Ebersbach G et al (2020) Efficacy of opicapone versus entacapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations: a post-hoc conservative analysis. Park Relat Disord 79:e61 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
doi: 10.1016/j.parkreldis.2020.06.231
Ferreira JJ, Lees A, Rocha JF et al (2016) Opicapone as an adjunct to levodopa in patients with Parkinson’s disease and end-of-dose motor fluctuations: a randomised, double-blind, controlled trial. Lancet Neurol 15:154–165
pubmed: 26725544
doi: 10.1016/S1474-4422(15)00336-1
Ferreira JJ, Lees JA, Poewe W et al (2018) Effectiveness of opicapone and switching from entacapone in fluctuating Parkinson disease. Neurology 90(21):e1849–e1857 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
pubmed: 29695590
doi: 10.1212/WNL.0000000000005557
Fründt O, Veliqi E, Schönwald B et al (2020) Die Hamburger Parkinson-Tagesklinik: Ein neues Behandlungskonzept an der Grenze zwischen stationärer und ambulanter Versorgung. Fortschr Neurol Psychiatr 88(6):362–337
pubmed: 32303075
doi: 10.1055/a-1083-6316
Gershanik OS (2015) Improving L‑dopa therapy: the development of enzyme inhibitors. Mov Disord 30:103–113
pubmed: 25335824
doi: 10.1002/mds.26050
Grosset DG, Macphee GJA, Nairn M (2010) Diagnosis and pharmacological management of Parkinson’s disease: summary of SIGN guidelines. BMJ 340:b5614
pubmed: 20068048
doi: 10.1136/bmj.b5614
Heinzel S, Berg D, Binder S et al (2018) Do we need to rethink the epidemiology and healthcare utilization of Parkinson’s disease in Germany? Front Neurol 9:500
pubmed: 30008693
pmcid: 6033992
doi: 10.3389/fneur.2018.00500
Jenner P, Rocha F, Ferreira JJ et al (2021) Redefining the strategy for the use of COMT inhibitors in Parkinson’s disease: the role of opicapone. Expert Rev Neurother. https://doi.org/10.1080/14737175.2021.1968298
doi: 10.1080/14737175.2021.1968298
pubmed: 34525893
Jost WH (2010) Gastrointestinal dysfunction in Parkinson’s disease. J Neurol Sci 289:69–73
pubmed: 19717168
doi: 10.1016/j.jns.2009.08.020
Klucken J, Barth J, Kugler P et al (2013) Unbiased and mobile gait analysis detects motor impairment in Parkinson’s disease. PLoS One 8(2):e56956
pubmed: 23431395
pmcid: 3576377
doi: 10.1371/journal.pone.0056956
Kuoppamäki M, Korpela K, Marttila R et al (2009) Comparison of pharmacokinetic profile of levodopa throughout the day between levodopa/carbidopa/entacapone and levodopa/carbidopa when administered four or five times daily. Eur J Clin Pharmacol 65:443–455
pubmed: 19229530
doi: 10.1007/s00228-009-0622-y
Lees A, Ferreira JJ, Rascol O et al (2017) Opicapone as adjunct to levodopa therapy in patients with Parkinson disease and motor fluctuations: a randomized clinical trial. JAMA Neurol 74(2):197–206
pubmed: 28027332
doi: 10.1001/jamaneurol.2016.4703
Lees A, Ferreira JJ, Poewe W et al (2020) Efficacy and safety/tolerability of opicapone in catechol-O-methyltransferase inhibitor-naïve Parkinson’s disease patients recently diagnosed with motor fluctuations. Park Relat Disord 79:e57 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
doi: 10.1016/j.parkreldis.2020.06.219
LeWitt PA (2008) Levodopa for the treatment of Parkinson’s disease. N Engl J Med 359(23):2468–2476
pubmed: 19052127
doi: 10.1056/NEJMct0800326
Liebermann A, Vijay M (2004) Wearing-off of levodopa of greatest concern for PD patients. J Neurol 11(Suppl 2):109
Lyte M (2010) Microbial endocrinology as a basis for improved L‑DOPA bioavailability in Parkinson’s patients treated for Helicobacter pylori. Med Hypotheses 74(5):895–897
pubmed: 19962247
doi: 10.1016/j.mehy.2009.11.001
National Institute for Health and Care Excellence (2006) Parkinson’s disease in over 20s: diagnosis and management. Clinical guideline [CG35]
Nyholm D, Lewnder T, Gomes-Trolin C et al (2012) Pharmacokinetics of levodopa/carbidopa microtablets versus levodopa/benserazide and levodopa/carbidopa in healthy volunteers. Clin Neuropharm 35(3):111–117
doi: 10.1097/WNF.0b013e31825645d1
Oertel WH, Berardelli A, Bloem BR et al (2011) Early (uncomplicated) Parkinson’s disease. In: European handbook of neurological management, Bd. 1, S 217–236
Oertel WH, Berardelli A, Bloem BR, Bonuccelli U, Burn D, Deuschl G, Trenkwalder C (2011) Late (complicated) Parkinson’s disease. In: European handbook of neurological management, Bd. 1, S 237–267
Olanow CW, Kieburtz K, Rascol O et al (2013) Factors predictive of the development of levodopa-induced dyskinesia and wearing-off in Parkinson’s disease. Mov Disord 28(8):1064–1071
doi: 10.1002/mds.25364
Reichmann H (2015) Therapie Tabellen Neurologie/Psychiatrie, 6. Aufl. Bd. 62. Westermayer, Pentenried, S 24
Rekdal VM, Bess EN, Bisanz JE et al (2019) Discovery and inhibition of an interspecies gut bacterial pathway for levodopa metabolism. Science 364(6445):eaau6323
pmcid: 7745125
doi: 10.1126/science.aau6323
Richter D, Bartig D, Jost WH et al (2019) Dynamics of device-based treatments for Parkinson’s disease in Germany from 2010 to 2017: application of continuous subcutaneous apomorphine, levodopa-carbidopa intestinal gel, and deep brain stimulation. J Neural Transm (Vienna) 126(7):879–888
doi: 10.1007/s00702-019-02034-8
Rocha F, Almeida L, Falcão A et al (2013) Opicapone: a short lived and very long acting novel catechol-O-methyltransferase inhibitor following multiple dose administration in healthy subjects. Br J Clin Pharmacol 76(5):763–775
pubmed: 23336248
pmcid: 3853535
doi: 10.1111/bcp.12081
Rocha J, Falcão A, Santos A et al (2014) Effect of opicapone and entacapone upon levodopa pharmacokinetics during three daily levodopa administrations. Eur J Clin Pharmacol 70:1059–1071
pubmed: 24925090
doi: 10.1007/s00228-014-1701-2
AWMF (2016) S3-Leitlinie Idiopathisches Parkinson-Syndrom. AWMF-Register-Nummer: 030-010
AWMF (2016) S3-Leitlinie Idiopathisches Parkinson-Syndrom. AWMF-Register-Nummer: 030-010 (adaptiert)
Salat D, Tolosa E (2013) Levodopa in the treatment of Parkinson’s disease: current status and new developments. J Parkinsons Dis 3(3):255–269
pubmed: 23948989
doi: 10.3233/JPD-130186
Scott NW, Macleod AD, Counsell CE (2016) Motor complications in an incident Parkinson’s disease cohort. Eur J Neurol 23(2):304–312
pubmed: 26074125
doi: 10.1111/ene.12751
Seemann P (2015) Parkinson’s disease treatment may cause impulse-control disorder via dopamine D3 receptors. Synapse 69:183–189
doi: 10.1002/syn.21805
Song Z, Zhang J, Xue T et al (2021) Different catechol-O-methyl transferase inhibitors in Parkinson’s disease: a Bayesian network meta-analysis. Front Neurol. https://doi.org/10.3389/fneur.2021.707723
doi: 10.3389/fneur.2021.707723
pubmed: 35185748
pmcid: 8739962
Stacy MA, Murphy JM, Greeley DR et al (2008) The sensitivity and specificity of the 9‑item wearing-off questionnaire. Park Relat Disord 14:205–212
doi: 10.1016/j.parkreldis.2007.07.013
Stocchi F, Coletti C, Bonassi S et al (2019) Early-morning OFF and levodopa dose failures in patients with Parkinson’s disease attending a routine clinical appointment using Time-to-ON Questionnaire. Eur J Neurol 26(5):821–826
pubmed: 30585679
doi: 10.1111/ene.13895
Stocchi F, Antonini A, Barone P et al (2014) Early DEtection of wEaring off in Parkinson disease: the DEEP study. Park Relat Disord 20(2):204–211
doi: 10.1016/j.parkreldis.2013.10.027
Stocchi F, Rascol O, Kieburtz K et al (2010) Initiating levodopa/carbidopa therapy with and without entacapone in early Parkinson disease: the STRIDE-PD study. Ann Neurol 68(1):18–27
pubmed: 20582993
doi: 10.1002/ana.22060
Sutton JP (2013) Dysphagia in Parkinson’s disease is responsive to levodopa. Park Relat Disord 19(3):282–284
doi: 10.1016/j.parkreldis.2012.11.007
Tambasco N, Romoli R, Calabresi P (2018) Levodopa in Parkinson’s disease: current status and future developments. Curr Neuropharmacol 16(8):1239–1252
pubmed: 28494719
pmcid: 6187751
doi: 10.2174/1570159X15666170510143821
Tönges L, Bartig D, Muhlack S et al (2019) Characteristics and dynamics of inpatient treatment of patients with Parkinson’s disease in Germany: analysis of 1.5 million patient cases from 2010 to 2015. Nervenarzt 90(2):167–174
pubmed: 30083879
doi: 10.1007/s00115-018-0590-5
Verschuur CVM, Suwijn SR, Boel JA et al (2019) Randomized delayed-start trial of levodopa in Parkinson’s disease. N Engl J Med 380:315–324
pubmed: 30673543
doi: 10.1056/NEJMoa1809983
Videnovic A, Poewe W, Lees A et al (2020) Effect of opicapone and entacapone on early morning-OFF pattern in Parkinson’s disease patients with motor fluctuations. Mov Disord 35(Suppl 1):S486–S487 (Poster presented at the Virtual International MDS Congress 2020, 12–16 September)
Woodrow H, Horne MK, Fernando CV et al (2020) A blinded, controlled trial of objective measurement in Parkinson’s disease. npj Park Dis 6:35
doi: 10.1038/s41531-020-00136-9
Zahoor I, Shafi A, Haq H et al (2018) Pharmacological treatment of Parkinson’s disease. In: Parkinson’s disease: pathogenesis and clinical aspects. Codon, Brisbane, S 129–144 (Chapter 7)
doi: 10.15586/codonpublications.parkinsonsdisease.2018.ch7